Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Becker, Jefferson; Ferreira, Lis Campos; Damasceno, Alfredo; Bichuetti, Denis Bernardi; Christo, Paulo Pereira; Callegaro, Dagoberto; Peixoto, Marco Aurélio Lana; Sousa, Nise Alessandra De Carvalho; Almeida, Sérgio Monteiro De; Adoni, Tarso; Santiago-Amaral, Juliana; Junqueira, Thiago; Pereira, Samira Luisa Apóstolos; Gomes, Ana Beatriz Ayroza Galvão Ribeiro; Pitombeira, Milena; Paolilo, Renata Barbosa; Grzesiuk, Anderson Kuntz; Piccolo, Ana Claudia; D´Almeida, José Arthur Costa; Gomes Neto, Antonio Pereira; Oliveira, Augusto Cesar Penalva De; Oliveira, Bianca Santos De; Tauil, Carlos Bernardo; Vasconcelos, Claudia Ferreira; Kaimen-Maciel, Damacio; Varela, Daniel; Diniz, Denise Sisterolli; Oliveira, Enedina Maria Lobato De; Malfetano, Fabiola Rachid; Borges, Fernando Elias; Figueira, Fernando Faria Andrade; Gondim, Francisco De Assis Aquino; Passos, Giordani Rodrigues Dos; Silva, Guilherme Diogo; Olival, Guilherme Sciascia Do; Santos, Gutemberg Augusto Cruz Dos; Ruocco, Heloisa Helena; Sato, Henry Koiti; Soares Neto, Herval Ribeiro; Cortoni Calia, Leandro; Gonçalves, Marcus Vinícius Magno; Vecino, Maria Cecilia Aragón De; Pimentel, Maria Lucia Vellutini; Ribeiro, Marlise De Castro; Boaventura, Mateus; Parolin, Mônica Koncke Fiuza; Melo, Renata Brant De Souza; Lázaro, Robson; Thomaz, Rodrigo Barbosa; Kleinpaul, Rodrigo; Dias, Ronaldo Maciel; Gomes, Sidney; Lucatto, Simone Abrante; Alves-Leon, Soniza Vieira; Fukuda, Thiago; Ribeiro, Taysa Alexandrino Gonsalves Jubé; Winckler, Thereza Cristina Dávila; Fragoso, Yara Dadalti; Nascimento, Osvaldo José Moreira Do; Ferreira, Maria Lucia Brito; Mendes, Maria Fernanda; Brum, Doralina Guimarães; Glehn, Felipe Von.
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;79(11): 1049-1061, Nov. 2021. tab
Artigo em Inglês | LILACS | ID: biblio-1350135

RESUMO

ABSTRACT The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.


RESUMO O DC de Neuroimunologia da ABN e o BCTRIMS trazem, nesse documento, as recomendações sobre vacinação da população com doenças desmielinizantes do sistema nervoso central (SNC) contra infecções em geral e contra o coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2), causador da COVID-19. Destaca-se a gravidade do atual momento frente ao avanço da COVID-19 em nosso País, o que torna mais evidente e importante a criação de guia de referência para orientação aos médicos, pacientes e autoridades de saúde pública quanto à vacinação, meio efetivo e seguro no controle de determinadas doenças infecciosa. O DCNI/ABN e o BCTRIMS recomendam que os pacientes com doenças desmielinizantes do SNC (ex., EM e NMOSD) sejam constantemente monitorados, quanto a atualização do seu calendário vacinal, especialmente, no início ou antes da mudança do tratamento com uma droga modificadora de doença (DMD). É importante também salientar que as vacinas são seguras e os médicos devem estimular o seu uso em todos os pacientes. Evidentemente, deve ser dada especial atenção às vacinas com vírus vivos atenuados. Por fim, é importante que os médicos verifiquem qual DMD o paciente está em uso e quando foi feita a sua última dose, pois cada fármaco pode interagir de forma diferente com a indução da resposta imune.


Assuntos
Humanos , COVID-19 , Esclerose Múltipla/tratamento farmacológico , Neurologia , Sistema Nervoso Central , Vacinação , SARS-CoV-2
2.
Arq Neuropsiquiatr ; 79(7): 598-606, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34468497

RESUMO

BACKGROUND: Recent changes to the diagnostic criteria for multiple sclerosis (MS) and new medications have had a major impact on the way in which specialists manage the disease. OBJECTIVE: To investigate factors considered by Brazilian neurologists in managing MS, and to identify how these contribute to diagnosis and treatment. METHODS: Potential participants were selected by a steering committee (MS experts who developed this survey). Only MS specialists were included in the study (neurologists who had completed a neuroimmunology fellowship or who were treating more than 30 MS patients). Links to the online questionnaire were distributed between March 2019 and January 2020. This questionnaire was composed of sections with hypothetical MS scenarios. RESULTS: Neurologists from 13 Brazilian states responded to the survey (n = 94). In the clinically isolated syndrome (CIS) scenario, the respondents agreed to treat patients with a high risk of MS diagnosis, whereas in the radiologically isolated syndrome (RIS) half of the respondents opted not to treat, even among high-risk patients. In cases of low-activity relapsing-remitting MS (RRMS), the choice of treatment was distributed among interferon beta, glatiramer acetate and teriflunomide, which were changed to fingolimod and natalizumab, as RRMS severity increased. The topics in which disagreement was found included practices regarding use of disease-modifying therapy (DMT) for pregnant patients and the washout period required for some DMTs. CONCLUSIONS: This study enabled identification of areas of agreement and disagreement about MS treatment among Brazilian neurologists, which can be used to update future protocols and improve patient management.


Assuntos
Esclerose Múltipla Recidivante-Remitente , Esclerose Múltipla , Feminino , Acetato de Glatiramer , Humanos , Imunossupressores/uso terapêutico , Esclerose Múltipla/diagnóstico , Esclerose Múltipla/tratamento farmacológico , Natalizumab/uso terapêutico , Neurologistas , Gravidez
3.
Mult Scler Relat Disord ; 50: 102806, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33588316

RESUMO

BACKGROUND: Basic steps in the management of patients with Multiple Sclerosis (MS), such as good patient understanding of the disease and active participation in its management are extremely important, as they directly influence treatment adherence and success. Therefore, this study aimed to evaluate the perception of MS patients and neurologists pertaining to the most common disease symptoms, disabilities that impact on quality of life, and patient concerns and difficulties during medical visits, as information that can be used to improve the doctor-patient relationship. METHODS: A cross-sectional study involving two groups: the first composed of neurologists and the second of patients. Participants of the first group were selected by a Steering Committee (15 predetermined neurologists representing each region of Brazil and specialized in MS and neuroimmunological disorders, who also assumed the role of creating the survey and questionnaire). Participants of the second group were selected following dissemination of a questionnaire on the AME's social networks (Amigos Múltiplos pela Esclerose, a non-governmental organization to support patients with MS). Questions about sociodemographic data, disease impact on quality of life, symptoms perception, and concerns and issues regarding disease care were put to both groups. RESULTS: A total of 317 patients and 182 neurologists answered the questionnaires. Significant divergences were found between the perceptions of patients and neurologists in relation to orientation and information given during medical appointments, and also regarding patient participation in treatment and therapy choice. Considering the topic assessing impact on quality of life, more than 70% of neurologists perceived that autonomy to work and travel, and future planning were aspects that most affected patient lives, however, almost 50% of patients reported that disease monitoring did not affect their life in any way. Analysis of data regarding MS symptoms revealed neurologists to consider physical symptoms, such as ambulation issues, imbalance, falls and urinary incontinence, to be those most interfering with patient quality of life, whereas patients considered non-physical symptoms, such as fatigue, pain, cognitive and memory problems to be more significant. Patients with primary progressive MS complained more about ambulation issues, imbalance and falls (p<0.05), when compared to patients with other disease phenotypes. CONCLUSION: Significant differences in disease perception were found in this study. While neurologists tended to overestimate the consequences and symptoms of the disease, for most patients, the disease impact on activities did not appear to be as significant, with more complaints regarding non-physical symptoms. Although neurologists described involving patients in treatment decisions and providing them with appropriate orientation during medical appointments, the opposite was reported by patients. These results may help to improve treatment adherence and disease outcomes by redefining the doctor-patient relationship.


Assuntos
Esclerose Múltipla , Brasil , Estudos Transversais , Humanos , Esclerose Múltipla/terapia , Neurologistas , Percepção , Relações Médico-Paciente , Qualidade de Vida
4.
Neurol Ther ; 8(2): 477-482, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31267407

RESUMO

INTRODUCTION: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. NMOSD starting after the age of 50 years is considered a "late onset" (LO-NMOSD) and seems to be particularly aggressive. The objective of this paper is to present a series of 37 Brazilian patients with LO-NMOSD. METHODS: Retrospective data collection from medical records of patients with LO-NMOSD seen at 14 Brazilian specialized units. RESULTS: The ratio of women to men in the sample was 4.3 to 1. The patients were followed up for a median period of 4 years. Sex, age at disease onset, and ethnic background were not associated with the number of relapses or disability outcomes. Extensive longitudinal myelitis affected 86% of patients, while optic neuritis affected 70%, and brainstem syndromes were present in only 16% of these patients. Six patients are currently using some type of support for walking or are wheelchair-bound. Three have died. Therapeutic options for NMOSD were particularly complicated for these elderly patients, since medications for controlling NMOSD are, in essence, immunosuppressive. Long-term use of corticosteroids can be an issue when the patients have high blood pressure, diabetes mellitus, or dyslipidemia (conditions often seen in elderly individuals). CONCLUSION: This series of LO-NMOSD cases highlights the importance of prompt diagnosis and treatment for these patients.

5.
Mult Scler Relat Disord ; 27: 392-396, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30504040

RESUMO

BACKGROUND: The 2015 criteria for diagnosing neuromyelitis optica spectrum disorder (NMOSD) have encouraged several groups across the world to report on their patients using these criteria. The disease typically manifests with severe relapses of optic neuritis, longitudinally extensive myelitis and/or brainstem syndromes, often leading to severe disability. Some patients are seropositive for antibodies against aquaporin-4 (AQP4), others are positive for anti-myelin oligodendrocyte glycoprotein (MOG), while a few are negative for both biomarkers. The disease is complex, and only now are specific therapeutic clinical trials being carried out. The present study adds to the literature through detailed clinical data from 153 medical records of Brazilian patients. METHODS: Retrospective assessment of medical records from nine specialized units in Brazil. RESULTS: NMOSD was more prevalent in females (4.1:1), who had significantly fewer relapses than males (p = 0.007) but presented similar levels of disability over time. African ancestry was associated with higher levels of disability throughout the disease course (p < 0.001), although the number of relapses was similar to that observed in white patients. Concomitant autoimmune diseases were relatively rare in this population (6.5%). Positivity for anti-AQP4 antibodies was identified in 62% of the patients tested, while 3% presented anti-MOG antibodies. Anti-AQP4 antibodies were not associated to worse disease course. The last medical record showed that six patients had died and 13 were wheelchair-bound. Seventy percent of the patients did not respond to first-line therapy (azathioprine and/or corticosteroids), and five patients continued to relapse even after four different courses of treatment. CONCLUSION: The present study adds to the reports from other countries presenting original data on Brazilian patients diagnosed with NMOSD according to the 2015 criteria.


Assuntos
Neuromielite Óptica/epidemiologia , Adolescente , Adulto , Idade de Início , Idoso , Aquaporina 4/imunologia , Brasil/epidemiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Glicoproteína Mielina-Oligodendrócito/imunologia , Neuromielite Óptica/diagnóstico , Neuromielite Óptica/imunologia , Índice de Gravidade de Doença , Adulto Jovem
6.
Arq Neuropsiquiatr ; 76(8): 539-554, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-30231128

RESUMO

The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.


Assuntos
Fatores Imunológicos/uso terapêutico , Imunossupressores/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Academias e Institutos , Brasil , Humanos , Neurologia , Recidiva , Vitamina D/uso terapêutico
7.
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;76(8): 539-554, Aug. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-950578

RESUMO

ABSTRACT The expanding therapeutic arsenal in multiple sclerosis (MS) has allowed for more effective and personalized treatment, but the choice and management of disease-modifying therapies (DMTs) is becoming increasingly complex. In this context, experts from the Brazilian Committee on Treatment and Research in Multiple Sclerosis and the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology have convened to establish this Brazilian Consensus for the Treatment of MS, based on their understanding that neurologists should be able to prescribe MS DMTs according to what is better for each patient, based on up-to-date evidence and practice. We herein propose practical recommendations for the treatment of MS, with the main focus on the choice and management of DMTs, as well as present a review of the scientific rationale supporting therapeutic strategies in MS.


RESUMO O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e personalizados, mas a escolha e o manejo das terapias modificadoras da doença (TMDs) tem se tornado cada vez mais complexos. Neste contexto, especialistas do Comitê Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla e do Departamento Científico de Neuroimunologia da Academia Brasileira de Neurologia reuniram-se para estabelecer este Consenso Brasileiro para o Tratamento da EM, baseados no entendimento de que neurologistas devem ter a possibilidade de prescrever TMDs para EM de acordo com o que é melhor para cada paciente, com base em evidências e práticas atualizadas. Por meio deste documento, propomos recomendações práticas para o tratamento da EM, com foco principal na escolha e no manejo das TMDs, e revisamos os argumentos que embasam as estratégias de tratamento na EM.


Assuntos
Humanos , Vitamina D/uso terapêutico , Fatores Imunológicos/uso terapêutico , Imunossupressores/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Recidiva , Brasil , Academias e Institutos , Neurologia
8.
Arq Neuropsiquiatr ; 76(5): 296-301, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29898075

RESUMO

INTRODUCTION: Psychiatric disorders frequently occur in patients with multiple sclerosis (MS); however, limited reports are available on these comorbidities. We aimed to investigate the relationships among MS, anxiety, depression, and suicidal ideation. METHODS: One hundred and thirty two patients with relapsing-remitting MS were evaluated using the Expanded Disability Status Scale, Beck Depression Inventory-II (BDI-II), Beck Scale for Suicide Ideation (BSI), and Hospital Anxiety and Depression Scale. RESULTS: A hierarchical regression analysis was performed to evaluate the variables. The regression equation significantly predicted the BSI score (R2 = 0.306; adjusted R2 = 0.273; F (9, 125) = 9.18; p < 0.0005), and the BDI-II score was the only variable that contributed significantly to this model (p < 0.0005). CONCLUSIONS: A high prevalence of depression and anxiety, and a higher rate of suicidal ideation were identified in MS patients compared to the general population. The presence of depressive symptoms appeared to have a direct influence on the risk of suicide.


Assuntos
Ansiedade/etiologia , Depressão/etiologia , Esclerose Múltipla Recidivante-Remitente/complicações , Ideação Suicida , Adolescente , Adulto , Idoso , Ansiedade/psicologia , Depressão/psicologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/psicologia , Escalas de Graduação Psiquiátrica , Fatores de Risco , Fatores Socioeconômicos , Adulto Jovem
9.
Arq. neuropsiquiatr ; Arq. neuropsiquiatr;76(5): 296-301, May 2018. tab
Artigo em Inglês | LILACS | ID: biblio-950540

RESUMO

ABSTRACT Psychiatric disorders frequently occur in patients with multiple sclerosis (MS); however, limited reports are available on these comorbidities. We aimed to investigate the relationships among MS, anxiety, depression, and suicidal ideation. Methods: One hundred and thirty two patients with relapsing-remitting MS were evaluated using the Expanded Disability Status Scale, Beck Depression Inventory-II (BDI-II), Beck Scale for Suicide Ideation (BSI), and Hospital Anxiety and Depression Scale. Results: A hierarchical regression analysis was performed to evaluate the variables. The regression equation significantly predicted the BSI score (R2 = 0.306; adjusted R2 = 0.273; F (9, 125) = 9.18; p < 0.0005), and the BDI-II score was the only variable that contributed significantly to this model (p < 0.0005). Conclusions: A high prevalence of depression and anxiety, and a higher rate of suicidal ideation were identified in MS patients compared to the general population. The presence of depressive symptoms appeared to have a direct influence on the risk of suicide.


RESUMO Transtornos psiquiátricos frequentemente ocorrem em pacientes com esclerose múltipla (EM). No entanto, os artigos sobre estas comorbidades são limitados. Pretendemos investigar as relações entre EM, ansiedade, depressão e ideação suicida. Métodos: Cento e trinta e dois pacientes com EM remitente-recorrente foram avaliados usando a Escala de Estado de Incapacidade Expandida, Inventário de Depressão de Beck-II (IDB-II), Escala de Beck para Ideação de Suicídio (BSI) e Escala de Ansiedade e Depressão. Resultados: Uma análise de regressão hierárquica foi realizada para avaliar as variáveis. A equação de regressão previu significativamente o escore BSI (R2 = 0,306; R2 ajustado = 0,273; F (9,125) = 9,18; p < 0,0005) e o escore no IDB-II foi a única variável que contribuiu significativamente para este modelo (p < 0,0005). Conclusões: Uma alta prevalência de depressão e ansiedade e uma maior taxa de ideação suicida foram identificadas em pacientes com EM em comparação com a população em geral. A presença de sintomas depressivos pareceu ter uma influência direta no risco de suicídio.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Ansiedade/etiologia , Depressão/etiologia , Ideação Suicida , Ansiedade/psicologia , Escalas de Graduação Psiquiátrica , Fatores Socioeconômicos , Fatores de Risco , Esclerose Múltipla Recidivante-Remitente/complicações , Esclerose Múltipla Recidivante-Remitente/psicologia , Depressão/psicologia
10.
Rev. bras. oftalmol ; 76(3): 133-137, maio-jun. 2017. tab
Artigo em Português | LILACS | ID: biblio-899054

RESUMO

RESUMO Objetivos: Determinar a freqüência e as características das alterações em exame oftalmológico, em exame de Tomografia de coerência óptica (OCT) do nervo e mácula e Campimetria em pacientes com Escrelose Multipla(EM). Métodos: Foram examinados 60 olhos sendo 30 de pacientes com o diagnóstico de EM e 30 de pacientes controles, atendidos no Hospital de Base do Distrito Federal. Os pacientes foram avaliados quanto aos parâmetros: características e alterações do exame oftalmológico, do OCT do nervo e da macula e Campimetria. Resultados: Os pacientes com EM apresentaram piores resultados em todos os parâmetros avaliados. No exame de campo visual Foram encontradas perdas localizadas em 50%. Em relação ao OCT de nervo óptico foi observado redução da camada de fibras nervosas em quadrantes temporal (p=0,0251) e inferior (p=0,0041), o OCT de mácula revelou diminuição da CFN principalmente nos quadrantes nasal interno (p=0,0002) e externo (p=0,0016),inferior interno (p=0,0007) e superior externo (p=0,0108) e interno (p=0,0046). Os pacientes com menores valores de espessura macular também tiveram piores resultados no campo visual (p=0,0001). Conclusão: Este estudo demonstrou que a EM é uma doença capaz de ocasionar alterações nos exames de OCT e Campo visual mesmo na ausência de sintomas visuais relatados pelos pacientes. A realização de exames como campo visual e de OCT de macula e nervo podem ser uma ferramenta útil para estimar o comprometimento pela doença e auxiliar no seguimento desses pacientes.


ABSTRACT Objectives: To determine the frequency and characteristics of alterations in ophthalmologic examinations of optic nerve and macula coherence tomography (OCT), and Campimetry in multiple sclerosis (MS) patients. Methods: Sixty eyes were examined, 30 of which were diagnosed with MS and 30 of the control patients, all attended at the General Hospital of the Federal District of Brazil. The patients were evaluated regarding the parameters: characteristics and alterations of the ophthalmological examination, OCT of the nerve and macula and Campimetry. Results: Patients with MS presented worse results in all parameters evaluated. On visual field examination localized losses were found in 50% of the cases . In relation to OCT of the optic nerve it was observed a reduction of the nerve fiber layer in temporal quadrants (p = 0.0251) and lower (p = 0.0041). The macular OCT revealed a decrease in the CFN, mainly in the internal nasal quadrants (p = 0.0002) and external (p = 0.0016), internal inferior (p = 0.0007) and external superior (p = 0.0108) plus internal (p = 0.0046). Patients with lower values of macular thickness also had worse results in the visual field (p = 0.0001). Conclusion: This study demonstrated that MS is a disease capable of causing changes in OCT and visual field tests even in the absence of visual symptoms reported by patients. Examinations such as visual field and OCT of macula and nerve can be a useful tool to estimate the damage by the disease and to assist in the follow-up of these patients


Assuntos
Humanos , Masculino , Feminino , Adulto , Transtornos da Visão/diagnóstico , Tomografia de Coerência Óptica , Testes de Campo Visual , Esclerose Múltipla/complicações , Nervo Óptico/diagnóstico por imagem , Transtornos da Visão/etiologia , Estudos de Casos e Controles , Epidemiologia Descritiva , Estudos Transversais , Técnicas de Diagnóstico Oftalmológico , Macula Lutea/diagnóstico por imagem , Fibras Nervosas/patologia
11.
Comun. ciênc. saúde ; 26(1/2): 223-236, jun 15, 2015. ilus
Artigo em Português | LILACS | ID: biblio-997014

RESUMO

O seio cavernoso é um sítio frequente de ocorrência de trombose séptica, frequentemente secundária a infecções de seios da face, órbitas, tonsilas, palato, dentes, seios esfenoidal e etmoidal. Este artigo relata o caso de uma paciente de 25 anos com sinusopatia que evoluiu com complicações após um mês apresentando anisocoria, ptose palpebral incompleta à direita, paralisia do olhar horizontal, paralisia facial central, queda de véu palatino, ausência de reflexo nauseoso à direita e desvio de língua para esquerda. Realizou exame de imagem que identificou acometimento de seio cavernoso e espessamento meníngeo adjacente. A tromboflebite do seio cavernoso (TSC) comumente afeta os nervos cranianos que o cruzam, constituindo-se em uma complicação incomum de infecções de pele, órbitas ou seios da face. A singularidade deste caso esteve na dificuldade de tratamento, no acometimento contínuo das meninges da base de crânio e, consequentemente, dos nervos cranianos dessa topografia (VII, IX e XII). O tratamento com anticoagulantes não é consenso na literatura, devido a complicações hemorrágicas que podem ocorrer no sítio do trombo. A importância do tratamento adequado e precoce das infecções dos seios esfenoidal e etmoidal, além de infecções de face, nariz, tonsilas, dentes e ouvidos evita disseminação bacteriana e complicações, como as descritas neste caso


The cavernous sinus is a rare site of septic thrombosis. It is associated with significant morbidity or mortality and is often related to local infection of the paranasal sinuses, orbits, tonsils, palate and teeth. This article presents a 25-year-old woman presented to our clinic with a history of anisocoria, right incomplete ptosis, horizontal gaze palsy, central facial palsy, right absence of garg reflex and left tongue deviation. Further work up with cranial magnetic resonance imaging revealed a meningeal enhancement at the skull base and signal alteration at the cavernous sinus suggestive of septic thrombosis. Cavernous sinus thrombophlebitis is a complication of skin, orbits or sinuses infections that typically causes cranial nerve palsies. We would like to emphasize that meningeal involvement at skull base can complicate the clinical course especially when there is involvement of multiple cranial nerves. Anticoagulation theraphy is not a consensus in the literature due to the risk of hemorrhagic complications that may occur on the site of the thrombus. The adequate and early treatment of infections of the sphenoid and ethmoidal sinuses, infections of nose, tonsils, teeth and ears can avoid bacterial disseminations and prevents complications, as described in this case.


Assuntos
Humanos , Feminino , Terapêutica , Tromboflebite , Tromboflebite/diagnóstico , Seio Cavernoso , Seio Esfenoidal , Tonsila Faríngea , Nervos Cranianos , Orelha , Seio Etmoidal , Infecções , Exame Neurológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA